PMID- 22931407
OWN - NLM
STAT- MEDLINE
DCOM- 20130429
LR  - 20181202
IS  - 1399-0039 (Electronic)
IS  - 0001-2815 (Linking)
VI  - 80
IP  - 5
DP  - 2012 Nov
TI  - HLA-B*15:02 is associated with anemia in patients with chronic hepatitis C 
      treated with pegylated interferon-alpha and ribavirin.
PG  - 424-30
LID - 10.1111/j.1399-0039.2012.01956.x [doi]
AB  - To investigate the relationship between human leukocyte antigen (HLA) class I and 
      II alleles and treatment-induced anemia in chronic hepatitis C (CHC) patients 
      receiving combination therapy with pegylated interferon-alpha (PEG-IFN-alpha) and 
      ribavirin (RBV). One hundred six naive CHC patients (59 females and 47 males; 
      mean age, 53.08 years) who underwent combination treatment were enrolled. The 
      patients were considered positive for hemoglobin (Hb)-related side effects if the 
      Hb concentrations dropped below 10 g/dl during PEG-IFN-alpha plus RBV treatment. The 
      HLA-A, -B, -C, -DR, and -DQ loci were investigated by sequence-based genotyping. 
      The effects of the clinical characteristics, virologic variables, and the HLA 
      alleles on treatment-induced anemia were evaluated by a logistic regression 
      analysis. Forty patients (37.7%) had Hb levels below 10 g/dl during the treatment 
      course. Low baseline Hb levels and an advanced liver fibrosis stage were 
      associated with decreases in Hb levels to below 10 g/dl. The occurrence of 
      treatment-related anemia (Hb < 10 g/dl) was significantly associated with 
      HLA-B*15:02 as shown by multivariate analysis (adjusted odds ratio, 8.13; 95% 
      confidence interval: 1.19-55.70; P-value after Holm's procedure, 0.03). 
      HLA-B*15:02 is associated with treatment-induced anemia in Taiwanese CHC patients 
      receiving combination therapy with PEG-IFN-alpha plus RBV.
CI  - (c) 2012 John Wiley & Sons A/S.
FAU - Tseng, C-W
AU  - Tseng CW
AD  - Department of Internal Medicine, Buddhist Dalin Tzu Chi General Hospital, 
      Chia-Yi, Taiwan.
FAU - Hsieh, Y-H
AU  - Hsieh YH
FAU - Chang, C-K
AU  - Chang CK
FAU - Lai, N-S
AU  - Lai NS
FAU - Hung, T-H
AU  - Hung TH
FAU - Wu, S-F
AU  - Wu SF
FAU - Tseng, K-C
AU  - Tseng KC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120830
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (Antiviral Agents)
RN  - 0 (HLA-B*15:02 antigen)
RN  - 0 (HLA-B15 Antigen)
RN  - 0 (Hemoglobins)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anemia/chemically induced/*genetics/immunology/virology
MH  - Antiviral Agents/administration & dosage/*adverse effects
MH  - Drug Therapy, Combination/adverse effects
MH  - Female
MH  - Genotype
MH  - HLA-B15 Antigen/*genetics/immunology
MH  - Hemoglobins/analysis
MH  - Hepacivirus/drug effects/physiology
MH  - Hepatitis C, Chronic/complications/*genetics/immunology/virology
MH  - Histocompatibility Antigens Class I/genetics/immunology
MH  - Histocompatibility Antigens Class II/genetics/immunology
MH  - Histocompatibility Testing
MH  - Humans
MH  - Interferon-alpha/administration & dosage/*adverse effects
MH  - Liver Cirrhosis/etiology/*genetics/immunology/virology
MH  - Male
MH  - Middle Aged
MH  - Polyethylene Glycols/administration & dosage/*adverse effects
MH  - Recombinant Proteins/administration & dosage/adverse effects
MH  - Ribavirin/administration & dosage/*adverse effects
MH  - Sequence Analysis, DNA
EDAT- 2012/08/31 06:00
MHDA- 2013/04/30 06:00
CRDT- 2012/08/31 06:00
PHST- 2012/03/03 00:00 [received]
PHST- 2012/06/30 00:00 [revised]
PHST- 2012/08/06 00:00 [accepted]
PHST- 2012/08/31 06:00 [entrez]
PHST- 2012/08/31 06:00 [pubmed]
PHST- 2013/04/30 06:00 [medline]
AID - 10.1111/j.1399-0039.2012.01956.x [doi]
PST - ppublish
SO  - Tissue Antigens. 2012 Nov;80(5):424-30. doi: 10.1111/j.1399-0039.2012.01956.x. 
      Epub 2012 Aug 30.